Browse the evidence

Sulfonylureas have fewer cardiovascular side effects and similar mortality to metformin, with clinically irrelevant weight gain and rare hypoglycemia.

Sulfonylureas are often viewed negatively, but they may have fewer heart-related side effects than metformin and do not significantly impact mortality. Weight gain is minimal, and low blood sugar is rare. They remain a safe and effective option for many patients.

Metabolic surgery (RYGB/VSG) improves glycemic control and induces T2DM remission through weight-loss-independent mechanisms, specifically by altering bile acid metabolism (FXR/TGR5 pathways), increasing incretin hormones (GLP-1/PYY), and modulating the gut microbiome, in addition to caloric restriction.

Metabolic surgery works by changing how your body processes food signals (hormones and bile acids), not just by making you eat less. This reset can lead to diabetes remission even before significant weight loss occurs, suggesting that the procedure alters the underlying biology of insulin resistance.

Metabolic surgery increases circulating levels of bile acids (BAs), which activate FXR and TGR5 receptors to suppress gluconeogenesis, improve insulin resistance, and stimulate GLP-1 secretion, thereby improving glucose homeostasis.

Surgery changes bile acid flow and concentration, which acts as a signaling molecule to tell the liver to stop producing excess sugar and to stimulate hormones that help insulin work better.

DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin) are cardiovascularly safe (neutral effect on MACE) but do not significantly reduce cardiovascular events or mortality compared to placebo.

DPP-4 inhibitors (like sitagliptin) are safe for your heart and do not increase the risk of heart attacks or strokes, but they also do not reduce these risks. They are a good option for blood sugar control if you cannot tolerate other drugs, but if you have existing heart disease, doctors usually prefer SGLT-2 inhibitors or GLP-1 agonists because those have proven heart benefits.

Moderate alcohol consumption (1-3 drinks/day) is associated with a significantly lower risk of coronary heart disease in women compared to abstainers, while heavy consumption increases risk.

For women aged 40-65 who do not smoke and have no history of heart disease, consuming 1-3 drinks per day is associated with a lower risk of coronary heart disease compared to not drinking at all. However, this does not apply to stroke risk, and heavy drinking increases risk. Individuals should consider their personal health history and local guidelines before making changes.

In nonobese humans, there is a weak inverse correlation between serum resistin and insulin sensitivity, but this association disappears when adjusting for body fat percentage.

In lean individuals, higher resistin levels are weakly associated with lower insulin sensitivity, but this is likely driven by body fat levels rather than resistin itself. Adjusting for body fat eliminates this link.

Mutations in the preproghrelin/ghrelin gene are associated with obesity in humans, suggesting a genetic basis for energy balance regulation via the ghrelin pathway.

If you have a family history of obesity, it may be partly due to genetics affecting your hunger hormones (ghrelin). This doesn't mean you are doomed, but it does mean you might need to be more mindful of hunger cues and food environments than someone without this genetic risk. Consult a healthcare provider for personalized advice.

In postmenopausal women who have never used hormone replacement therapy, greater waist circumference is significantly associated with an increased risk of invasive breast cancer, independent of overall body mass index.

If you are postmenopausal, your body shape matters for breast cancer risk, not just your weight. Specifically, carrying more weight around your waist increases your risk, even if your overall weight (BMI) is healthy. This risk is most pronounced if you do not take hormone replacement therapy. To mitigate this, focus on reducing central adiposity through lifestyle changes, as waist circumference is a stronger predictor of risk than BMI alone in this group.

In postmenopausal women, the association between central adiposity (waist circumference) and breast cancer risk is significantly modified by hormone replacement therapy use, with the association being strongest in never-users and non-significant in current users.

If you are postmenopausal and take hormone replacement therapy, your breast cancer risk is elevated regardless of your waist size. However, if you do not take hormones, keeping your waist circumference low is a critical way to reduce your risk. The protective effect of a smaller waist is most visible in those not taking hormones.

In patients with type 2 diabetes, total adipocyte number is significantly lower than in BMI-matched obese subjects, indicating a failure of adipose tissue hyperplasia (cell number increase) to buffer excess fat.

For individuals with Type 2 Diabetes, the body's ability to expand fat storage capacity by creating new fat cells (hyperplasia) is impaired compared to non-diabetic obese individuals. This leads to larger existing fat cells (hypertrophy) and forces excess fat into visceral organs and muscles, worsening insulin resistance. Management should focus on preventing further fat accumulation to avoid ectopic fat deposition, as the structural capacity to store fat safely in subcutaneous tissue is limited.

Calorie restriction reduces the production of Prostaglandin E2 (PGE2), a suppressive factor for T-cells, which contributes to enhanced immune function.

Reducing calories, especially by 30%, lowers PGE2, a compound that suppresses T-cells. This reduction helps your immune system work better.

Obesity is associated with a blunted increase in muscle sympathetic nerve activity (MSNA) in response to oral glucose ingestion, despite higher plasma insulin levels, which may contribute to reduced thermic effect of food.

In obesity, the body's ability to increase energy expenditure (via sympathetic nervous system activation) in response to eating is impaired. This blunted response, despite high insulin levels, likely contributes to a lower thermic effect of food, making weight management more difficult. This is a physiological feature of insulin resistance, not just a behavioral issue.

Higher white blood cell (WBC) counts in obese individuals are largely mediated by elevated fasting plasma leptin concentrations, which stimulate haemopoietic stem cell proliferation.

If you are obese, your body produces more leptin, which signals your bone marrow to produce more white blood cells. This is a normal physiological response to higher body fat levels, not necessarily a sign of infection or disease. Understanding this link helps contextualize lab results in the context of body composition.

Elevated cholesteryl ester transfer protein (CETP) activity is significantly higher in South Asians compared to Europeans and drives the characteristic atherogenic dyslipidemia (high triglycerides, high LDL particle number, low HDL-C) observed in this population.

For South Asian individuals, standard cholesterol tests (LDL-C) may underestimate cardiovascular risk. It is critical to assess lipoprotein particle numbers (via NMR or ApoB) and CETP activity if available, as elevated CETP drives the formation of small, dense LDL particles and low HDL, which are strong predictors of heart disease in this population.

Standard diagnostic biomarkers (BNP/NT-proBNP) are less reliable in obese patients with HF due to lower circulating levels caused by increased clearance by adipose tissue, requiring lower cut-off values for diagnosis.

If you are obese and have heart failure symptoms, standard blood tests for heart failure (BNP/NT-proBNP) might show lower levels than expected, even if you have the condition. Doctors should use lower thresholds to diagnose you. Do not assume a 'normal' result means you don't have heart failure if you have symptoms.

Novel antidiabetic agents, specifically SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, exert significant anti-inflammatory effects in the cardiovascular and renal systems, contributing to improved cardiorenal outcomes in type 2 diabetes.

If you have Type 2 Diabetes, ask your doctor about newer medications like SGLT-2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively reduce inflammation in your blood vessels and kidneys, which helps prevent heart attacks, strokes, and kidney failure. This benefit is independent of how well they control your glucose levels.

GLP-1 receptor agonists reduce cardiovascular inflammation by activating AMPK and CAMKKβ signaling pathways, leading to the downregulation of pro-inflammatory genes and increased SIRT6 expression.

This technical mechanism explains why GLP-1 drugs protect blood vessels. By activating specific cellular 'switches' (AMPK and SIRT6), these drugs turn off inflammatory genes in the vessel walls, preventing plaque buildup and stiffness.

DPP-4 inhibitors reduce systemic inflammation by suppressing the secretion of IL-6 and IL-1β and inhibiting NF-κB nuclear translocation, leading to improved endothelial function and plaque stabilization.

DPP-4 inhibitors (like sitagliptin) help stabilize heart disease plaques by reducing the inflammatory signals (IL-6, IL-1β) that attract immune cells to artery walls. This reduces the risk of plaque rupture and heart attacks.

The 'Dual Intervention Point' (DIP) model proposes that physiological regulation is weak within a 'zone of indifference' (dynamic equilibrium) but becomes strong only when fatness crosses upper or lower intervention points.

Your body's regulatory 'alarm bells' (hunger/satiety signals) may be quiet when you are within a normal weight range (zone of indifference). Strong physiological corrections only happen when you move significantly outside this range (crossing intervention points).

Pima Indian males exhibit significantly lower beta-adrenergic sensitivity (higher chronotropic dose-25) compared to Caucasian males, independent of body fat levels.

This research highlights that Pima Indian men may have a biological baseline of lower heart rate responsiveness to beta-adrenergic stimulation compared to Caucasian men, regardless of weight. This is a physiological trait, not a lifestyle failure. It may contribute to lower hypertension rates but higher obesity prevalence in this population. Focus on overall health metrics rather than trying to force a 'Caucasian' physiological response.

In males, increased adiposity is associated with decreased beta-adrenergic sensitivity, whereas this correlation is absent in females.

For men, carrying more body fat tends to blunt the heart's responsiveness to adrenaline-like signals. This link is not seen in women in this study. This suggests that weight management strategies might need to consider sex-specific physiological responses to adiposity.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with a 19% increased risk of incident atrial fibrillation (AF), with risk escalating as liver disease severity (fibrosis/MASH) increases.

If you have MASLD, you have a significantly higher risk of developing atrial fibrillation, even in early stages. Managing metabolic risk factors (weight, blood sugar, blood pressure) is not just about liver health but is a critical strategy for preventing heart rhythm disorders. Early detection and comprehensive management of MASLD are crucial to mitigate this dual burden.

Obesity and Obstructive Sleep Apnea (OSA) exacerbate the risk of AF in MASLD through hemodynamic changes, epicardial fat deposition, and sympathetic nervous system activation.

For MASLD patients, managing weight and treating sleep apnea are critical for preventing AF. These conditions add mechanical and inflammatory stress to the heart, which can be mitigated through lifestyle and medical interventions.

Basal glucose homeostasis is governed by insulin-independent mechanisms primarily regulated by the brain, whereas glucose tolerance is determined by the interaction between insulin secretion and insulin sensitivity.

Understanding that fasting blood sugar (basal state) and how your body handles meals (glucose tolerance) are controlled by different systems can explain why some treatments work for one but not the other. Fasting glucose is largely managed by brain-mediated, insulin-independent processes, while meal response relies on insulin. This suggests that therapies targeting the brain (like certain GLP-1 agonists) may help basal glucose even if they don't fully restore insulin sensitivity.